Market Overview:
The global OX40 receptor agonist market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, myasthenia gravis, and psoriasis. Additionally, the increasing demand for targeted therapies is also contributing to the growth of this market. The global OX40 receptor agonist market can be segmented on the basis of type into fully human IgG2 agonist ab, humanised IgG1 agonist mAb, and fully human IgG1 agonist mAb. On the basis of application, this market can be segmented into cancers (such as leukemia and lymphoma), myasthenia gravis (a neuromuscular disorder), and psoriasis (a chronic skin disease). This market can also be segmented on the basis of region into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
An agonist is a molecule that binds to a receptor and initiates a response by the target cell. OX40 receptor agonists are drugs that stimulate activity of the OX40 receptor, which is involved in regulation of immune responses. They are being investigated as potential treatments for conditions such as inflammation, cancer, and autoimmune diseases.
Fully Human IgG2 Agonist Ab:
Fully human IgG2 Agonist Ab, it's usage and growth factor in OX40 receptor agonist market? Fully human IgG2 Agonist Ab, it's usage and growth factor in OX40 receptor agonist market? Fully human IgG2 Agonist Ab, it's usage.
Humanised IgG1 Agonist mAb:
Humanized IgG1 is a type of antibody, which means it is a protein made by one our immune system cells, in this case the white blood cell. These proteins are used to fight bacteria and viruses that want to do harm to us. The antibodies can attach themselves onto the surface of these foreign objects and bring them into our own cells for destruction. This process is called immunization or antibody binding.
Application Insights:
The cancer segment dominated the global OX40 receptor agonist market in 2017 and is expected to maintain its dominance over the forecast period. This can be attributed to increasing prevalence of various types of cancer, such as lung, breast and colorectal cancers. For instance, according to data published by WHO in 2018, around 1 in 6 women develop some form of breast cancer during their lifetime while about 1 in 5 men are estimated to develop prostate cancer during their lifetime. These statistics indicate a significant increase in demand for effective treatment options for these diseases which is likely drive growth over the forecast period.
Psoriasis application segment is also expected register notable gains owing to high product penetration rates used for psoriasis treatment across various regions coupled with growing awareness regarding this disease among individuals aged 40 years and above due to changing lifestyles along with environmental factors such as UV radiation exposure that may trigger psoriatic arthritis or plaque formation.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing awareness levels are some of the factors responsible for its continued dominance over the forecast period. In addition, rising incidence rates of cancer and other autoimmune diseases have led to an increase in demand for these products in this region.
Asia Pacific is expected to be one of the fastest-growing regions during the forecast period owing to a rise in healthcare expenditure by governments as well as private agencies coupled with growing initiatives undertaken by pharmaceutical companies for expanding their presence in this region. Moreover, increasing prevalence rate of cancer is also anticipated to drive growth during this period due to high unmet clinical needs along with rapidly improving healthcare infrastructure facilities across emerging economies such as China & India will further propel regional growth over next eight years (Ongoing Developments).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the OX40 receptor agonist market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for OX40 receptor agonists over the forecast period.
- Rising awareness about immunotherapy: The rising awareness about immunotherapy as a treatment option for various types of cancers is another key factor driving growth in the OX40 receptor agonist market. Immunotherapy involves using substances that stimulate or restore immune system function to fight diseases such as cancer and has been shown to be more effective than traditional chemotherapy treatments in some cases. This growing awareness about immunotherapy is expected to boost demand for OX40 receptor agonists over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
OX40 Receptor Agonist Market Research Report
By Type
Fully Human IgG2 Agonist Ab, Humanised IgG1 Agonist mAb, Fully Human IgG1 Agonist mAb
By Application
Cancers, Myasthenia Gravis, Psoriasis
By Companies
Merk, Pfizer, GlaxoSmithKline, Glenmark, AstraZeneca (MedImmune), Roche, Agenus, Bristol Myers Squibb, Bioinvent, Sorrento Therapeutics, Incyte
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
128
Number of Tables & Figures
90
Customization Available
Yes, the report can be customized as per your need.
Global OX40 Receptor Agonist Market Report Segments:
The global OX40 Receptor Agonist market is segmented on the basis of:
Types
Fully Human IgG2 Agonist Ab, Humanised IgG1 Agonist mAb, Fully Human IgG1 Agonist mAb
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancers, Myasthenia Gravis, Psoriasis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merk
- Pfizer
- GlaxoSmithKline
- Glenmark
- AstraZeneca (MedImmune)
- Roche
- Agenus
- Bristol Myers Squibb
- Bioinvent
- Sorrento Therapeutics
- Incyte
Highlights of The OX40 Receptor Agonist Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Fully Human IgG2 Agonist Ab
- Humanised IgG1 Agonist mAb
- Fully Human IgG1 Agonist mAb
- By Application:
- Cancers
- Myasthenia Gravis
- Psoriasis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the OX40 Receptor Agonist Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
OX40 receptor agonist is a type of medication that binds to the OX40 receptor on cells and causes them to activate. This can lead to the production of proteins that help fight infections, inflammation, and cancer.
Some of the major players in the ox40 receptor agonist market are Merk, Pfizer, GlaxoSmithKline, Glenmark, AstraZeneca (MedImmune), Roche, Agenus, Bristol Myers Squibb, Bioinvent, Sorrento Therapeutics, Incyte.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 OX40 Receptor Agonist Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 OX40 Receptor Agonist Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 OX40 Receptor Agonist Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the OX40 Receptor Agonist Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global OX40 Receptor Agonist Market Size & Forecast, 2020-2028
4.5.1 OX40 Receptor Agonist Market Size and Y-o-Y Growth
4.5.2 OX40 Receptor Agonist Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Fully Human IgG2 Agonist Ab
5.2.2 Humanised IgG1 Agonist mAb
5.2.3 Fully Human IgG1 Agonist mAb
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancers
6.2.2 Myasthenia Gravis
6.2.3 Psoriasis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global OX40 Receptor Agonist Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 OX40 Receptor Agonist Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Fully Human IgG2 Agonist Ab
9.6.2 Humanised IgG1 Agonist mAb
9.6.3 Fully Human IgG1 Agonist mAb
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancers
9.10.2 Myasthenia Gravis
9.10.3 Psoriasis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Fully Human IgG2 Agonist Ab
10.6.2 Humanised IgG1 Agonist mAb
10.6.3 Fully Human IgG1 Agonist mAb
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancers
10.10.2 Myasthenia Gravis
10.10.3 Psoriasis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Fully Human IgG2 Agonist Ab
11.6.2 Humanised IgG1 Agonist mAb
11.6.3 Fully Human IgG1 Agonist mAb
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancers
11.10.2 Myasthenia Gravis
11.10.3 Psoriasis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Fully Human IgG2 Agonist Ab
12.6.2 Humanised IgG1 Agonist mAb
12.6.3 Fully Human IgG1 Agonist mAb
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancers
12.10.2 Myasthenia Gravis
12.10.3 Psoriasis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Fully Human IgG2 Agonist Ab
13.6.2 Humanised IgG1 Agonist mAb
13.6.3 Fully Human IgG1 Agonist mAb
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancers
13.10.2 Myasthenia Gravis
13.10.3 Psoriasis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 OX40 Receptor Agonist Market: Competitive Dashboard
14.2 Global OX40 Receptor Agonist Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merk
14.3.2 Pfizer
14.3.3 GlaxoSmithKline
14.3.4 Glenmark
14.3.5 AstraZeneca (MedImmune)
14.3.6 Roche
14.3.7 Agenus
14.3.8 Bristol Myers Squibb
14.3.9 Bioinvent
14.3.10 Sorrento Therapeutics
14.3.11 Incyte
